Prague Med. Rep. 2021, 122, 243-256
https://doi.org/10.14712/23362936.2021.22
Therapeutic Drug Monitoring of Protein Kinase Inhibitors in Breast Cancer Patients
References
1. , H. A. 3rd, Hurwitz, H. I., Dees, E. C., Dowlati, A., Blackwell, K. L., O’Neil, B., Marcom, P. K., Ellis, M. J., Overmoyer, B., Jones, S. F., Harris, J. L., Smith, D. A., Koch, K. M., Stead, A., Mangum, S., Spector, N. L. (2005) Phase I safety, pharmacokinetics, and clinical activity study of lapatinib (GW572016), a reversible dual inhibitor of epidermal growth factor receptor tyrosine kinases, in heavily pretreated patients with metastatic carcinomas. J. Clin. Oncol. 23, 5305–5313.
<https://doi.org/10.1200/JCO.2005.16.584>
2. , H. A. 3rd, Taylor, C. W., Jones, S. F., Koch, K. M., Versola, M. J., Arya, N., Fleming, R. A., Smith, D. A., Pandite, L., Spector, N., Wilding, G. (2009) A phase I and pharmacokinetic study of oral lapatinib administered once or twice daily in patients with solid malignancies. Clin. Cancer Res. 15, 6702–6708.
<https://doi.org/10.1158/1078-0432.CCR-09-0369>
3. , H. J., Sun, Y., Dirix, L. Y., Jiang, Z., Paridaens, R., Tan, A. R., Awada, A., Ranade, A., Jiao, S., Schwartz, G., Abbas, R., Powell, C., Turnbull, K., Vermette, J., Zacharchuk, C., Badwe, R. (2010) Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer. J. Clin. Oncol. 28, 1301–1307.
<https://doi.org/10.1200/JCO.2009.25.8707>
4. , E., Guidi, M., Blanchet, B., Schneider, M. P., Decosterd, L. A., Buclin, T., Csajka, C., Widmer, N. (2020) Therapeutic drug monitoring of targeted anticancer protein kinase inhibitors in routine clinical use: A critical review. Ther. Drug Monit. 42, 33–44.
<https://doi.org/10.1097/FTD.0000000000000699>
5. , A. J., Munster, P. N., Melisko, M. E., Rugo, H. S., Park, J. W., Goga, A., Auerback, G., Khanafshar, E., Ordovas, K., Koch, K. M., Moasser, M. M. (2014) Phase I dose-escalation study of 5-day intermittent oral lapatinib therapy in patients with human epidermal growth factor receptor 2-overexpressing breast cancer. J. Clin. Oncol. 32, 1472–1479.
<https://doi.org/10.1200/JCO.2013.52.1161>
6. , Q. S., Cianfrocca, M. E., Goldstein, L. J., Gale, M., Murray, N., Loftiss, J., Arya, N., Koch, K. M., Pandite, L., Fleming, R. A., Paul, E., Rowinsky, E. K. (2008) A phase I and pharmacokinetic study of lapatinib in combination with letrozole in patients with advanced cancer. Clin. Cancer Res. 14, 4484–4490.
<https://doi.org/10.1158/1078-0432.CCR-07-4417>
7. , M., Bouchalova, K., Friedecky, D., Polynkova, A., Janostakova, A., Radova, L., Cwiertka, K., Trojanec, R., Zezulova, M., Zlevorova, M., Hajduch, M., Melichar, B. (2012) High lapatinib plasma levels in breast cancer patients: risk or benefit? Tumori 98, 162–165.
<https://doi.org/10.1177/030089161209800123>
8. , G., Criscitiello, C., Esposito, A., Intra, M., Minucci, S. (2017) Pharmacokinetic drug evaluation of ribociclib for the treatment of metastatic, hormone-positive breast cancer. Expert Opin. Drug Metab. Toxicol. 13, 575–581.
<https://doi.org/10.1080/17425255.2017.1318848>
9. , M., Falkowski, S., Saint-Marcoux, F., Monchaud, C., Picard, N., Laroche, M. L., Tubiana-Mathieu, N., Venat-Bouvet, L., Marquet, P., Woillard, J. B. (2017) Towards therapeutic drug monitoring of everolimus in cancer? Results of an exploratory study of exposure-effect relationship. Pharmacol. Res. 121, 138–144.
<https://doi.org/10.1016/j.phrs.2017.04.029>
10. , S., Woillard, J. B. (2019) Therapeutic drug monitoring of everolimus in oncology: Evidences and perspectives. Ther. Drug Monit. 41, 568–574.
<https://doi.org/10.1097/FTD.0000000000000628>
11. , K. T., Lorusso, P. M., Demichele, A., Abramson, V. G., Courtney, R., Randolph, S. S., Shaik, M. N., Wilner, K. D., O’Dwyer, P. J., Schwartz, G. K. (2012) Phase I, dose-escalation trial of the oral cyclin-dependent kinase 4/6 inhibitor PD 0332991, administered using a 21-day schedule in patients with advanced cancer. Clin. Cancer Res. 18, 568–576.
<https://doi.org/10.1158/1078-0432.CCR-11-0509>
12. , R. A., Gelman, R. S., Agar, N. Y. R., Santagata, S., Randall, E. C., Gimenez-Cassina Lopez, B., Connolly, R. M., Dunn, I. F., Van Poznak, C. H., Anders, C. K., Melisko, M. E., Silvestri, K., Cotter, C. M., Componeschi, K. P., Marte, J. M., Moy, B., Blackwell, K. L., Puhalla, S. L., Ibrahim, N., Moynihan, T. J., Nangia, J., Tung, N., Burns, R., Rimawi, M. F., Krop, I. E., Wolff, A. C., Winer, E. P., Lin, N. U.; Translational Breast Cancer Research Consortium (TBCRC) (2020) Pre- and postoperative neratinib for HER2-positive breast cancer brain metastases: Translational Breast Cancer Research Consortium 022. Clin. Breast Cancer 20, 145–151.e2.
<https://doi.org/10.1016/j.clbc.2019.07.011>
13. , Y., Tamura, K., Kondo, S., Tanabe, Y., Iwasa, S., Shimomura, A., Kitano, S., Ogasawara, K., Turner, P. K., Mori, J., Asou, H., Chan, E. M., Yamamoto, N. (2016) Phase 1 study of abemaciclib, an inhibitor of CDK 4 and 6, as a single agent for Japanese patients with advanced cancer. Cancer Chemother. Pharmacol. 78, 281–288.
<https://doi.org/10.1007/s00280-016-3085-8>
14. , B., Yeap, S., Clements, A., Balakrishnar, B., Wong, M., Gurney, H. (2012) Evidence for therapeutic drug monitoring of targeted anticancer therapies. J. Clin. Oncol. 30, 4017–4025.
<https://doi.org/10.1200/JCO.2012.43.5362>
15. , A., Barthelemy, P., Awada, A. (2015) Evaluating the pharmacokinetics and pharmacodynamics of everolimus for treating breast cancer. Expert Opin. Drug Metab. Toxicol. 11, 823–834.
<https://doi.org/10.1517/17425255.2015.1013464>
16. , P., Palmieri, L. J., Funck-Brentano, C., Paci, A., Flippot, R., Mir, O., Coriat, R. (2019) Major pitfalls of protein kinase inhibitors prescription: A review of their clinical pharmacology for daily use. Crit. Rev. Oncol. Hematol. 141, 112–124.
<https://doi.org/10.1016/j.critrevonc.2019.06.006>
17. , S. L., Mathijssen, R. H. J., Beijnen, J. H., Huitema, A. D. R., Steeghs, N. (2019) Individualized dosing of oral targeted therapies in oncology is crucial in the era of precision medicine. Eur. J. Clin. Pharmacol. 75, 1309–1318.
<https://doi.org/10.1007/s00228-019-02704-2>
18. , S. L., Martinez-Chavez, A., van Dongen, M. G. J., Beijnen, J. H., Schinkel, A. H., Huitema, A. D. R., Steeghs, N. (2020) Clinical pharmacokinetics and pharmacodynamics of the cyclin-dependent kinase 4 and 6 inhibitors palbociclib, ribociclib, and abemaciclib. Clin. Pharmacokinet. 59, 1501–1520.
<https://doi.org/10.1007/s40262-020-00930-x>
19. , P., Thivat, E., Richard, D., Roche, L., Dohou, J., Pouget, M., Eschalier, A., Durando, X., Authier, N. (2016) Therapeutic drug monitoring and tyrosine kinase inhibitors. Oncol. Lett. 12, 1223–1232.
<https://doi.org/10.3892/ol.2016.4780>
20. , J. R., Cassier, P. A., Gerecitano, J. F., Witteveen, P. O., Chugh, R., Ribrag, V., Chakraborty, A., Matano, A., Dobson, J. R., Crystal, A. S., Parasuraman, S., Shapiro, G. I. (2016) A phase I study of the cyclin-dependent kinase 4/6 inhibitor ribociclib (LEE011) in patients with advanced solid tumors and lymphomas. Clin. Cancer Res. 22, 5696–5705.
<https://doi.org/10.1158/1078-0432.CCR-16-1248>
21. , D. H., Fisher, D. S., Spicer, J., Flanagan, R. J. (2013) Clinical pharmacokinetics of tyrosine kinase inhibitors: Implications for therapeutic drug monitoring. Ther. Drug Monit. 35, 562–587.
<https://doi.org/10.1097/FTD.0b013e318292b931>
22. , G. I., Meier-Wiedenbach, I., Manns, M. P. (2004) Clinical pharmacokinetics of everolimus. Clin. Pharmacokinet. 43, 83–95.
<https://doi.org/10.2165/00003088-200443020-00002>
23. , H. J., Samer, C. F., Mathijssen, R. H., Schellens, J. H., Gurney, H. (2011) Moving towards dose individualization of tyrosine kinase inhibitors. Cancer Treat. Rev. 37, 251–260.
<https://doi.org/10.1016/j.ctrv.2010.08.006>
24. , H. R., Chaix, M., Gombos, A., Aftimos, P., Awada, A. (2016) Pharmacodynamics, pharmacokinetics and clinical efficacy of neratinib in HER2-positive breast cancer and breast cancer with HER2 mutations. Expert Opin. Drug Metab. Toxicol. 12, 947–957.
<https://doi.org/10.1080/17425255.2016.1198317>
25. , J. M., Kaplan, B., Tedesco Silva, H., Kahan, B. D., Dantal, J., Vitko, S., Boger, R., Rordorf, C. (2002) Exposure-response relationships for everolimus in de novo kidney transplantation: Defining a therapeutic range. Transplantation 73, 920–925.
<https://doi.org/10.1097/00007890-200203270-00016>
26. , T. M., Wolfe, T. A., Ryan, J. C. (2018) Updates on managing advanced breast cancer with palbociclib combination therapy. Ther. Adv. Med. Oncol. 10, 1758835918793849.
<https://doi.org/10.1177/1758835918793849>
27. , H., Shimizu, C., Masuda, N., Ohtani, S., Ohno, S., Takahashi, M., Yamamoto, Y., Nishimura, R., Sato, N. Ohsumi, S., Iwata, H., Mori, Y., Hashigaki, S., Muramatsu, Y., Nagasawa, T., Umeyama, Y., Lu, D. R., Toi, M. (2019) Palbociclib in combination with letrozole in patients with estrogen receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: PALOMA-2 subgroup analysis of Japanese patients. Int. J. Clin. Oncol. 24, 274–287.
<https://doi.org/10.1007/s10147-018-1353-9>
28. , A., Rosen, L. S., Tolaney, S. M., Tolcher, A. W., Goldman, J. W., Gandhi, L., Papadopoulos, K. P., Beeram, M., Rasco, D. W., Hilton, J. F., Nasir, A., Beckmann, R. P., Schade, A. E., Fulford, A. D., Nguyen, T. S., Martinez, R., Kulanthaivel, P., Li, L. Q., Frenzel, M., Cronier, D. M., Chan, E. M., Flaherty, K. T., Wen, P. Y., Shapiro, G. I. (2016) Efficacy and safety of abemaciclib, an inhibitor of CDK4 and CDK6, for patients with breast cancer, non-small cell lung cancer, and other solid tumors. Cancer Discov. 6, 740–753.
<https://doi.org/10.1158/2159-8290.CD-16-0095>
29. , A., Urva, S. R., Grosch, K., Cheung, W. K., Anak, O., Sellami, D. B. (2014) Relationship between everolimus exposure and safety and efficacy: Meta-analysis of clinical trials in oncology. Eur. J. Cancer 50, 486–495.
<https://doi.org/10.1016/j.ejca.2013.11.022>
30. , T. S., Dhuria, S., Lu, Y., Laisney, M., Yang, S., Grandeury, A., Mueller-Zsigmondy, M., Umehara, K., Huth, F., Miller, M., Germa, C., Elmeliegy, M. (2018) Ribociclib bioavailability is not affected by gastric pH changes or food intake: In silico and clinical evaluations. Clin. Pharmacol. Ther. 104, 374–383.
<https://doi.org/10.1002/cpt.940>
31. , H., Colonna, M. (2019) Breast cancer epidemiology. Presse Med. 48, 1076–1084. (in French)
<https://doi.org/10.1016/j.lpm.2019.09.022>
32. , A., Bloomquist, E., Tang, S., Fu, W., Bi, Y., Liu, Q., Yu, J., Zhao, P., Palmby, T. R., Goldberg, K. B., Chang, C. J. G., Patel, P., Alebachew, E., Tilley, A., Pierce, W. F., Ibrahim, A., Blumenthal, G. M., Sridhara, R., Beaver, J. A., Pazdur, R. (2018) FDA approval: Ribociclib for the treatment of postmenopausal women with hormone receptor-positive, HER2-negative advanced or metastatic breast cancer. Clin. Cancer Res. 24, 2999–3004.
<https://doi.org/10.1158/1078-0432.CCR-17-2369>
33. , M., Hesselink, D. A., Holt, D. W., Billaud, E. M., van Gelder, T., Kunicki, P. K., Brunet, M., Budde, K., Barten, M. J., De Simone, P., Wieland, E., Lopez, O. M., Masuda, S., Seger, C., Picard, N., Oellerich, M., Langman, L. J., Wallemacq, P., Morris, R. G., Thompson, C., Marquet, P. (2016) Therapeutic drug monitoring of everolimus: A consensus report. Ther. Drug Monit. 38, 143–169.
<https://doi.org/10.1097/FTD.0000000000000260>
34. , J., Mann, J. (2016) Specialty pharmacy services for patients receiving oral medications for solid tumors. Am. J. Health Syst. Pharm. 73, 775–796.
<https://doi.org/10.2146/ajhp150863>
35. , G., Pannier, D., Sakji, I., Villain, A., Feutry, F., Marliot, G. (2020) Advantages of everolimus therapeutic drug monitoring in oncology when drug-drug interaction is suspected: a case report. J. Oncol. Pharm. Pract. 26, 1743–1749.
<https://doi.org/10.1177/1078155220904761>
36. , S., Yamaguchi, H., Kawasaki, Y., Kikuchi, M., Tanaka, M., Ito, A., Mano, N. (2019) Long-term relationship between everolimus blood concentration and clinical outcomes in Japanese patients with metastatic renal cell carcinoma: a prospective study. J. Pharm. Health Care Sci. 5, 6.
<https://doi.org/10.1186/s40780-019-0135-5>
37. , K., Mukai, H., Naito, Y., Yonemori, K., Kodaira, M., Tanabe, Y., Yamamoto, N., Osera, S., Sasaki, M., Mori, Y., Hashigaki, S., Nagasawa, T., Umeyama, Y., Yoshino, T. (2016) Phase I study of palbociclib, a cyclin-dependent kinase 4/6 inhibitor, in Japanese patients. Cancer Sci. 107, 755–763.
<https://doi.org/10.1111/cas.12932>
38. , S. C., Cai, S., Ajamie, R. T., Burke, T., Beckmann, R. P., Chan, E. M., De Dios, A., Wishart, G. N., Gelbert, L. M., Cronier, D. M. (2014) Semi-mechanistic pharmacokinetic/pharmacodynamic modeling of the antitumor activity of LY2835219, a new cyclin-dependent kinase 4/6 inhibitor, in mice bearing human tumor xenografts. Clin. Cancer Res. 20, 3763–3774.
<https://doi.org/10.1158/1078-0432.CCR-13-2846>
39. , S. C., Sykes, A. K., Kulanthaivel, P., Chan, E. M., Turner, P. K., Cronier, D. M. (2018) A population pharmacokinetic and pharmacodynamic analysis of abemaciclib in a phase I clinical trial in cancer patients. Clin. Pharmacokinet. 57, 335–344.
<https://doi.org/10.1007/s40262-017-0559-8>
40. , A., Mouillet, G., Nguyen Tan Hon, T., Montcuquet, P., Maurina, T., Almotlak, H., Stein, U., Montange, D., Foubert, A., Nerich, V., Pivot, X., Royer, B. (2014) Impact of everolimus blood concentration on its anti-cancer activity in patients with metastatic renal cell carcinoma. Cancer Chemother. Pharmacol. 73, 999–1007.
<https://doi.org/10.1007/s00280-014-2435-7>
41. , M., Schmidt, M. (2018) Management of adverse events during cyclin-dependent kinase 4/6 (CDK4/6) inhibitor-based treatment in breast cancer. Ther. Adv. Med. Oncol. 10, 1758835918793326.
<https://doi.org/10.1177/1758835918793326>
42. , N. P., Gelderblom, H., Guchelaar, H. J. (2009) Clinical pharmacokinetics of tyrosine kinase inhibitors. Cancer Treat. Rev. 35, 692–706.
<https://doi.org/10.1016/j.ctrv.2009.08.004>
43. , R. B., Yu, H., Schellens, J. H. M., Beijnen, J. H., Steeghs, N., Huitema, A. D. R. (2017) Practical recommendations for therapeutic drug monitoring of kinase inhibitors in oncology. Clin. Pharmacol. Ther. 102, 765–776.
<https://doi.org/10.1002/cpt.787>
44. , R. B., Atrafi, F., Schellens, J. H. M., Beijnen, J. H., Huitema, A. D. R., Mathijssen, R. H. J., Steeghs, N. (2018) Pharmacokinetic optimization of everolimus dosing in oncology: A randomized crossover trial. Clin. Pharmacokinet. 57, 637–644.
<https://doi.org/10.1007/s40262-017-0582-9>
45. , A., de Geus-Oei, L. F., de Boer, M., Tol, J., Kamm, Y., de Jong, P. C., Jonker, M. A., Vos, A. H., Grootjans, W., de Groot, J. W. B., Mulder, S. F., Aarntzen, E., Gerritsen, W. R., van Herpen, C. M. L., van Erp, N. P. (2018) Everolimus exposure and early metabolic response as predictors of treatment outcomes in breast cancer patients treated with everolimus and exemestane. Target Oncol. 13, 641–648.
<https://doi.org/10.1007/s11523-018-0596-8>
46. , K. K., Fracasso, P. M., Bukowski, R. M., Lynch, T. J., Munster, P. N., Shapiro, G. I., Janne, P. A., Eder, J. P., Naughton, M. J., Ellis, M. J., Jones, S. F., Mekhail, T., Zacharchuk, C., Vermette, J., Abbas, R., Quinn, S., Powell, C., Burris, H. A. (2009) A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors. Clin. Cancer Res. 15, 2552–2558.
<https://doi.org/10.1158/1078-0432.CCR-08-1978>
47. , H., Steeghs, N., Nijenhuis, C. M., Schellens, J. H., Beijnen, J. H., Huitema, A. D. (2014) Practical guidelines for therapeutic drug monitoring of anticancer tyrosine kinase inhibitors: Focus on the pharmacokinetic targets. Clin. Pharmacokinet. 53, 305–325.
<https://doi.org/10.1007/s40262-014-0137-2>
48. , J., Yang, N., Ji, D., Shen, W., Li, W., Han, R., Wang, N., Tao, H., Chapman, S. C., Sykes, A. K., Zhang, W., Hu, X. (2021) A randomized phase I study of abemaciclib in Chinese patients with advanced and/or metastatic cancers. Target Oncol. 16, 177–187.
<https://doi.org/10.1007/s11523-020-00789-9>
